Canadian nod for Otsuka/Lundbeck's Abilify Maintena
This article was originally published in Scrip
Canada has become the latest market to approve Abilify Maintena, the once-monthly intramuscular injection formulation of Otsuka Pharmaceutical's atypical antipsychotic aripiprazole.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.